Prostate cancer (module 4) Flashcards

1
Q

anatomy and size of the prostate gland

A

sits at the base of the bladder, in front of the rectum
weighs approx 20g, size of a walnut

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

the prostate gland is responsible for producing

A

30% of seminal fluid
seminal fluid contains enzymes indluding prostate specificc antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

incidence of prostate cancer

A

most common cancer for Australian men
often occurs after the age of 50
more prevalent in African men and less prevalent in Asian men

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

risks factors for prostate cancer

A

genetic - family history increases risk
race - more often affects African men
dietary factors - may have a role but are controversial, high dietary fat is a risk factor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

early disease in prostate cancer

A

early disease is usually asymptomatic
patients who present with LUTS usually have an enlarged prostate secondary to BPH though prostate cancer may coexist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

locally advanced disease symptoms

A

urinary symptoms similar to those in BPH
eg. frequency, nostril, hesitancy, poor stream, dysuria
haematuria may be present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

metastatic disease symptoms

A

bone pain, fractures, cord compression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

investigations for diagnosis of prostate cancer

A

digital rectal examination
- firm nodule is usually T2 disease
- hard, craggy prostate is usually T3 disease
PSA test
trans-rectal ultrasound biopsy (TRUS biopsy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TRUS biopsy

A

performed as a day case under local anaesthetic, sedation or general anaesthetic
biopsies taken through the rectum under ultrasound visualisation
usually 12 biopsies taken

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

potential complications of TRUS biopsy

A

infection - (all pts get prophylaxis but infections can still occur)
bleeding - all pts may see blood PR, but serious post biopsy bleeding can also occur, all patients should stop anti coagulating drugs before biopsy
urinary retention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how long might normal bleeding be seen after a TRUS biopsy

A

PR blood, haematuria and haematospermia may last several weeks
anti coagulating drugs must be stopped before a TRUS biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how many biopsies should be taken in a trus biopsy

A

usually like 12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

is PSA prostate specific

A

yes but it is not cancer specific

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are some conditions that can cause elevated PSA

A

benign prostatic hyperplasia BPH
urinary tract infections
instrumentation eg. catheter
idiopathic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the chances that the patient has cancer if the PSA is elevated but there’s no urinary tract infection?

A

PSA 4-10ng/ml = 25% chance
PSA >10ng/ml = 50% chance
PSA > 20ng/ml = 90% chance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what should patients with elevated age related PSA have?

A

a DRE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what percentage of prostate cancer will be missed on DRE alone

A

45%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what percentage of prostate cancer will be missed on PSA testing alone

19
Q

what investigations might be used for staging of prostate cancer

A

DRE (clinically)
CT or MRI pelvis
Isotope bone scan

20
Q

what do you use to grade prostate cancer

A

prostate biopsy - Gleason score

21
Q

what is the Gleason score

A

used for grading prostate cancer
gives prognostic information and indicator of tumour aggression
histological grading system 1-5

22
Q

95% of prostate tumours are

A

adenocarcinoma

23
Q

indication for radical prostatectomy

A

localised prostate cancer
has been shown to improve survival in these men

24
Q

how is a radical prostatectomy performed

A

can be performed as open retropubic operation or laparoscopically with or without robotic assistance

25
what length of stay will be needed for radical prostatectomy
approx 5 days or more, less if the operation was laparoscopic
26
post operative management after radical prostatectomy
catheter left in situ for 10 days post operatively not to be removed as reinsertion may disrupt urethral anastomosis
27
complications of radical prostatectomy
impotence incontinence recusancy of disease mortality
28
two types of radiotherapy for prostate cancer
external beam radiotherapy (EBRT) brachytherapy
29
external beam radiotherapy
given in fractions delivered over several weeks 3 dimensional conformational and intensity modulated techniques allow increased dose to be delivered to the prostate whilst minimising dose to rectum and other structures
30
what is brachytherapy
implanting radioactive material into the prostate
31
two types of brachytherapy
seed brachytherapy high dose rate brachytherapy
32
seed brachytherapy
permanently implanting radioactive seeds (iodine or palladium) into the prostate
33
high dose rate brachytherapy
temporary insertion of a high dose radioactive source to give a boost of treatment to the prostate usually combined with EBRT for high risk locally advanced disease
34
complications of radiotherapy
bladder and bowel irritation e.g. proctitis impotence disease recurrence
35
androgen suppression agents
prostate cancer is a testosterone dependant tumour androgens may be suppressed by - surgical castration - LHRH agonist - anti-androgens - oestrogens
36
LHRH agonist examples
goserelin (zoladex) leupropelin (lucrin)
37
anti-androgens examples
cyproterone acetate biclutamide
38
when should androgen suppression be prescribed
androgen suppression with an LHRH agonist is usually a palliative treatment but has been shown to improve survival when used in the adjuvant setting with radiotherapy
39
advanced prostate cancer treatment
40% of patients present with advanced disease mean survival 3-3.5 years usually require hormone manipulation GnRH agonist most frequently used therapy
40
bone complications from prostate cancer
testosterone is essential in maintaining bone mass in men and androgen suppression causes osteopenia and osteoporosis bone metastasis are common bone pain, fracture, spinal cord compression
41
should prostate cancer be screened for?
prostate cancer screening is controversial and there is little evidence suggesting that it would improve survival rates
42
at what point does prostate cancer become symptomatic
usually only once it is advanced
43
is prostate cancer usually curable?
yes
44
does increased PSA level confirm a prostate cancer diagnosis?
no, you need histological diagnosis via a TRUS biopsy